Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration
In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of au...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (246 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 03900nam-a2201129z--4500 | ||
|---|---|---|---|
| 001 | 993545018704498 | ||
| 005 | 20231214133348.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202205s2022 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5680000000037686 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/81005 | ||
| 035 | |a (EXLCZ)995680000000037686 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Kodjikian, Laurent |4 edt | |
| 245 | 1 | 0 | |a Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (246 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients’ quality of life. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a aflibercept monotherapy | ||
| 653 | |a polypoidal choroidal vasculopathy | ||
| 653 | |a neovascular age-related macular degeneration | ||
| 653 | |a good baseline visual acuity | ||
| 653 | |a ForeseeHome AMD Monitoring System® | ||
| 653 | |a AREDS2-HOME study | ||
| 653 | |a age-related macular degeneration | ||
| 653 | |a exudation | ||
| 653 | |a optical coherence tomography angiography | ||
| 653 | |a anti-vascular endothelial growth factor | ||
| 653 | |a brolucizumab | ||
| 653 | |a epithelial tear | ||
| 653 | |a optical coherence tomography | ||
| 653 | |a Sorsby's fundus dystrophy | ||
| 653 | |a Sorsby | ||
| 653 | |a hereditary retinal dystrophy | ||
| 653 | |a choroidal neovascularisation | ||
| 653 | |a macular neovascularization | ||
| 653 | |a anti-VEGF treatment | ||
| 653 | |a long-term FU | ||
| 653 | |a treatment outcome | ||
| 653 | |a emerging treatment | ||
| 653 | |a neovascular age-related macular degeneration (nAMD) | ||
| 653 | |a Vascular Endothelial Growth Factor (VEGF) | ||
| 653 | |a cataract surgery | ||
| 653 | |a clinical trials | ||
| 653 | |a real-world evidence | ||
| 653 | |a AMD | ||
| 653 | |a oct-angiography | ||
| 653 | |a fellow eye | ||
| 653 | |a choriocapillaris | ||
| 653 | |a quiescent macular neovascularization | ||
| 653 | |a ranibizumab | ||
| 653 | |a aflibercept | ||
| 653 | |a anti-VEGF | ||
| 653 | |a visual acuity | ||
| 653 | |a reading acuity | ||
| 653 | |a disease activity | ||
| 653 | |a treatment change | ||
| 653 | |a treat and extend | ||
| 653 | |a switch therapy | ||
| 653 | |a retina | ||
| 653 | |a choroidal neovascularization | ||
| 653 | |a angiogenesis | ||
| 653 | |a meteorin | ||
| 653 | |a therapeutic innovation | ||
| 653 | |a prevention | ||
| 653 | |a nutrients | ||
| 653 | |a lifestyle | ||
| 653 | |a treatment-naive | ||
| 653 | |a anti-vascular endothelial growth factor | ||
| 653 | |a cardiovascular risk factors | ||
| 653 | |a arterial hypertension | ||
| 653 | |a macula-off rhegmatogenous detachment | ||
| 653 | |a superficial perifoveal capillary plexus | ||
| 653 | |a retinal deep perifoveal capillary plexus | ||
| 653 | |a identification | ||
| 653 | |a risk | ||
| 653 | |a Delphi | ||
| 653 | |a STARS® | ||
| 653 | |a food supplement | ||
| 653 | |a bevacizumab | ||
| 653 | |a meta-analysis | ||
| 653 | |a meta-regression | ||
| 653 | |a age-related macular degeneration (AMD) | ||
| 653 | |a comparative therapies | ||
| 653 | |a effectiveness | ||
| 653 | |a intravitreal anti-vascular endothelial growth factor | ||
| 653 | |a treat-and-extend | ||
| 653 | |a pro re nata regimen | ||
| 776 | |z 3-0365-3930-1 | ||
| 776 | |z 3-0365-3929-8 | ||
| 700 | 1 | |a Kodjikian, Laurent |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:51:36 Europe/Vienna |f system |c marc21 |a 2022-05-14 21:41:54 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337828200004498&Force_direct=true |Z 5337828200004498 |b Available |8 5337828200004498 | ||